U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556757) titled 'A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia' on July 28, 2025.
Brief Summary: This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.
Study Start Date: April 11, 2025
Study Type: INTERVENTIONAL
Condition:
B-ALL
Leukemia
Intervention:
DRUG: CD19 t-haNK
IV infusion of CD19 t-haNK
Recruitment Status: RECRUITING
Sponsor: ImmunityBio, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....